Survival Analysis

# Survival Analysis
## Introduction to Global Health Data Science
### <a href="https://sta198f2021.github.io/website/">Back to Website</a>
### Prof. Amy Herring

---

layout: true
 
<div class="my-footer">

<a href="https://sta198f2021.github.io/website/" target="_blank">Back to website</a>

</div>

---

# Survival Data

---

## Goal

Survival analysis is a complex topic!  The goal of our coverage is to give you the skills you need to understand results of simple descriptive statistics in this setting, and we will not have time to discuss more complex modeling of survival data in this course. Come see me in the future if you need to analyze survival data!

---

## Examples

In many studies, the outcome of interest is the amount of time from an initial observation until the occurrence of some event of interest, e.g.
  - Time from transplant surgery until new organ failure
  - Time to death in a pancreatic cancer trial
  - Time to first sex
  - Time to menarche
  - Time to divorce
  - Time to graduation

Typically, the event of interest is called a *failure* (even if it is a good thing).   The time interval between a starting point and the failure is known as the *survival time* and is often represented by `$t$`.

---

## Characteristics of Survival Data

Certain aspects of survival data make data analysis particularly challenging. 
  - Typically, not all the individuals are observed until their times of failure
    - An organ transplant recipient may die in an automobile accident before the new organ fails
    - A student may withdraw to start a multi-billion dollar health company
    - Not everyone gets divorced
    - A pancreatic cancer patient may move to Aitutaki instead of undergoing further treatment
  - In this case, an observation is said to be *right censored* at the last point of contact
  
  
When you hear someone talk about *censoring*, typically they mean *right censoring*, but there are other types of censoring that you may encounter.
  
---

## Censoring

Data may be censored in multiple ways:

- Right censored: the usual type of censoring in health data, accommodated by standard models. In this case you see a study participant at the beginning of the study, but you may not follow them until the outcome occurs (or the outcome may never occur)
  
  - Left censored: a study participant may have experienced the event before the study begins. For example, you may want to study when kindergarteners reach a certain reading level, but some may be proficient readers already at the start of your study.
  
  - Interval censored: you don't know exactly when an event happened, only that it happened between two times. For example, if a patient enrolled in a cancer screening study is cancer-free at the time of the first screening, `$t_1$` but has cancer at the time of the second screening, `$t_2$`, you only know that cancer developed sometime after `$t_1$` but before `$t_2$`

---

## Calendar Time and Participant Time

It is important to distinguish between calendar time and participant time. In this plot, an "X" at the end of a line represents a failure, and an "O" represents a censored observation.

---

<img src="img/studytime.png" width="70%" style="display: block; margin: auto;" />
 - A study may start enrolling patients in September and continue until all 500 patients have been enrolled
 - This is likely to take months or years
 - Time is typically converted from calendar time to participant time (time between enrollment and failure or censoring) before analysis

---

The distribution of survival times is characterized by the *survival function*, represented by `$S(t)$`.  For a continuous random variable `$T$`, `$$S(t)=Pr(T>t)$$` and `$S(t)$` represents the proportion of individuals who have not yet failed.

The graph of `$S(t)$` versus `$t$` is called a survival curve.  The survival curve shows the proportion of survivors at any given time.

---

## Survival of Children in Burkina Faso by Vaccination Status

---

# Estimating Survival Curves

---

## Small Study of 10 Patients
.pull-left[
| Patient | Event time `$x$` | Event type |
|------:|-------:|---------:|
| 1 | 4.5 | Death |
| 2 | 7.5 | Death |
| 3 | 8.5 | Censored | 
| 4 | 11.5 | Death |
| 5 | 13.5 | Censored | 
| 6 | 15.5 | Death |
| 7 | 16.5 | Death |
| 8 | 17.5 | Censored | 
| 9 | 19.5 | Death |
| 10 | 21.5 | Censored |
]

---

## Kaplan-Meier Estimate

Perhaps the most popular estimate of a survival curve is the *Kaplan-Meier* or *product-limit* estimate.  This method is actually fairly intuitive. Define the following quantities.
  - `$I_t$`:  \# at risk of failure at time `$t$`; those who did not fail before `$t$` and those who were not censored before `$t$`; also known as the *risk set*
  - `$d_t$`:  \# who fail at time `$t$`
  - `$q_t=\frac{d_t}{I_t}$`:  estimated probability of failing at time `$t$`
  - `$S(t)$`:  cumulative probability of surviving beyond time `$t$`, estimated as 
`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right).$$`
  - the `$\prod$` symbol is for multiplication, e.g. `$\prod_{i=1}^3 x_i=x_1x_2x_3$` and `$\prod_{i=1}^5i=1 \times 2 \times 3 \times 4 \times 5$`.

---

## Intutive how?

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

At each time `$t$`, the probability of surviving is just `$1-Pr(failing)$` (remember the complement rule, also know as the law of total probability!).  Before there are any failures in the data, our estimated `$\hat{S}(t)=1$`.  At the time of the first failure, this probability falls below 1 and is simply one minus the probability of failing at that time, or `$1-\frac{\# ~ failures}{\#~at ~ risk~ of~ failing}$`.

After the first failure, things get more complicated.  At the time of the second failure, you can calcuate `$1-\frac{\# ~ failures}{\# ~ at ~risk ~  of ~ failing}$`, but this doesn't provide the whole picture, as someone else has already died.  In fact, this is the *conditional probability* of surviving now that you've made it past the time of the first failure.

---

## Welcome Back, Probability!

I promised you'd see probability laws again!  :)

Coming back to you next:  the multiplicative rule!

---

## Multiplicative Rule Saves the Day!

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

How do you then calculate the total (unconditional) probability of survival?  That is just the product of the probability of surviving past the first failure times the conditional probability of surviving beyond the second failure given that you made it past the first, or

.small[
$$Pr(\text{survive past first and second times}) $$
`$$=Pr(\text{survive past first time})Pr(\text{survive past second time} \mid \text{survive past first time})$$`
`$$=\left(1-\frac{\# ~ failures ~at ~failure~ time~ 1}{\# ~at~ risk ~of ~failing ~at ~failure ~time ~1}\right)\left(1-\frac{\# ~of ~ failures ~ at ~ failure ~ time~  2}{\# ~ at ~ risk ~ of ~ failing ~ at ~ failure~  time~ 2}\right)$$`
]

If someone is censored, they are no longer at risk of failing at the next failure time and are taken out of the *risk set* and out of the calculation.

---

### Kaplan-Meier (KM) Estimate

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | | |
| 4.5 | 1 | 0 | | |
| 7.5 | 1 | 0 | | |
| 8.5 | 0 | 1 | | |
| 11.5 | 1 | 0 | | |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

.pull-right[
`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`
Remember `$d_t$` is the # who fail at time `$t$`, and `$I_t$` is the # at risk of failure at time `$t$` (have not been censored and have not failed)

]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | | |
| 7.5 | 1 | 0 | | |
| 8.5 | 0 | 1 | | |
| 11.5 | 1 | 0 | | |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

`$\hat{S}(0)=1$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | $$1 \times \left(1-\frac{1}{10}=0.9\right)$$ |
| 7.5 | 1 | 0 | | |
| 8.5 | 0 | 1 | | |
| 11.5 | 1 | 0 | | |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 4.5}) $$
$$=Pr(\text{survive past time 0}) $$
`$$\times Pr(\text{survive past time 4.5} \mid \text{survive past time 0})$$`
]

]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | $$0.9 \times \left(1-\frac{1}{9}\right)=0.8$$ |
| 8.5 | 0 | 1 | | |
| 11.5 | 1 | 0 | | |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 7.5}) $$
`$$=Pr(\text{survive past time 4.5})$$`
`$$\times Pr(\text{survive past time 7.5} \mid \text{survive past time 4.5})$$`
]

]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | $$0.8 \times \left(1-\frac{0}{8}\right)=0.8$$ |
| 11.5 | 1 | 0 | | |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 8.5}) $$
`$$=Pr(\text{survive past time 7.5})$$`
`$$\times Pr(\text{survive past time 8.5} \mid \text{survive past time 7.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | $$0.8 \times \left(1-\frac{1}{7}\right)=0.69$$ |
| 13.5 | 0 | 1 | | |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

$$Pr(\text{survive past time 11.5}) $$
`$$=Pr(\text{survive past time 8.5})$$`
`$$\times Pr(\text{survive past time 11.5} \mid \text{survive past time 8.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 6 | $$0.69 \times \left(1-\frac{0}{6}\right)=0.69$$ |
| 15.5 | 1 | 0 | | |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 13.5}) $$
`$$=Pr(\text{survive past time 11.5})$$`
`$$\times Pr(\text{survive past time 13.5} \mid \text{survive past time 11.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 5 | 0.69 |
| 15.5 | 1 | 0 | 4 | $$0.69 \times \left(1-\frac{1}{5}\right)=0.552$$ |
| 16.5 | 1 | 0 | | |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 15.5}) $$
`$$=Pr(\text{survive past time 13.5})$$`
`$$\times Pr(\text{survive past time 15.5} \mid \text{survive past time 13.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 5 | 0.69 |
| 15.5 | 1 | 0 | 4 | 0.552 |
| 16.5 | 1 | 0 | 3 | $$0.552 \times \left(1-\frac{1}{4}\right)=0.414$$ |
| 17.5 | 0 | 1 | | |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 16.5}) $$
`$$=Pr(\text{survive past time 15.5})$$`
`$$\times Pr(\text{survive past time 16.5} \mid \text{survive past time 15.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 5 | 0.69 |
| 15.5 | 1 | 0 | 4 | 0.552 |
| 16.5 | 1 | 0 | 3 | 0.414 |
| 17.5 | 0 | 1 | 2 | $$0.414 \times \left(1-\frac{0}{3}\right)=0.414$$ |
| 19.5 | 1 | 0 | | |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 17.5}) $$
`$$=Pr(\text{survive past time 16.5})$$`
`$$\times Pr(\text{survive past time 17.5} \mid \text{survive past time 16.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 5 | 0.69 |
| 15.5 | 1 | 0 | 4 | 0.552 |
| 16.5 | 1 | 0 | 3 | 0.414 |
| 17.5 | 0 | 1 | 2 | 0.414 |
| 19.5 | 1 | 0 | 1 | $$0.414 \times \left(1-\frac{1}{2}\right)=0.207$$ |
| 21.5 | 0 | 1 | | |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 19.5}) $$
`$$=Pr(\text{survive past time 17.5})$$`
`$$\times Pr(\text{survive past time 19.5} \mid \text{survive past time 17.5})$$`

]
]

---

| `$t$` | # Failed: `$d_t$` | # Censored | # Left: `$I_{t+1}$` | `$\hat{S}(t)$` |
|------:|-------:|---------:|------:|------:|
| 0.0 | 0 | 0 | 10 | 1 |
| 4.5 | 1 | 0 | 9 | 0.9 |
| 7.5 | 1 | 0 | 8 | 0.8 |
| 8.5 | 0 | 1 | 7 | 0.8 |
| 11.5 | 1 | 0 | 6 | 0.69 |
| 13.5 | 0 | 1 | 5 | 0.69 |
| 15.5 | 1 | 0 | 4 | 0.552 |
| 16.5 | 1 | 0 | 3 | 0.414 |
| 17.5 | 0 | 1 | 2 | 0.414 |
| 19.5 | 1 | 0 | 1 | 0.207 |
| 21.5 | 0 | 1 | 1 | $$0.207 \times \left(1-\frac{0}{1}\right)=0.207$$ |
]
]

`$$\hat{S}(t)=\prod_{t_i \leq t} \left(1-\frac{d_{t_i}}{I_{t_i}}\right)$$`

$$Pr(\text{survive past time 21.5}) $$
`$$=Pr(\text{survive past time 19.5})$$`
`$$\times Pr(\text{survive past time 21.5} \mid \text{survive past time 19.5})$$`

]
]

---

## KM Estimate

In between failure times, the KM estimate does not change but is constant.  This gives the estimated survival function its step-like appearance (we call this type of function a *step function*).

---

## Tumors in Children, 2012 *Neuro-Oncology*

<img src="img/atct.png" width="90%" style="display: block; margin: auto;" />
]
.pull-right[
- Which biomarker values are associated with the best survival?
- Which values are associated with the worst survival?
- What is the median survival time in the group with the smallest ATCT values?
 - Median survival is the time at which `$\hat{S}(t)=0.5$`
- If a child is in the group with the largest ATCT values, what is their estimated 5-year survival probability?
]

---

## Lung Cancer Data

The `lung` dataset is available from the `survival` package in R. The data contain subjects with advanced lung cancer. Variables include the following.

`time`: Survival time in days

`status`: censoring status 1=censored, 2=dead (failure) (note:  another common coding recognized by R is to let 0=censored and 1=failure)

`ph.ecog`: Eastern Cooperative Oncology Group (ECOG) performance score, where 0=asymptomatic, 1=symptomatic but ambulatory, 2=in bed <50% of day, 3=in bed >50% of day but not bedbound, 4=bedbound

---

## KM Plot for Lung Cancer Data

.panelset[
.panel[.panel-name[Plot]
<img src="w15-l01-survival_files/figure-html/unnamed-chunk-6-1.png" width="60%" style="display: block; margin: auto;" />
]
.panel[.panel-name[Code]

```r
library(survival)
library(survminer)

ggsurvplot(
  fit = survfit(Surv(time, status)~ph.ecog, data=lung),
  title = "Survival by Performance Score",
  xlab = "Days",
  ylab = "Survival probability"
)
```
]
]
---

## Estimating Median Survival

One quantity of interest is the median survival time.

```r
survfit(Surv(time, status) ~ ph.ecog, data = lung)
```

```
#> Call: survfit(formula = Surv(time, status) ~ ph.ecog, data = lung)
#> 
#>    1 observation deleted due to missingness 
#>             n events median 0.95LCL 0.95UCL
#> ph.ecog=0  63     37    394     348     574
#> ph.ecog=1 113     82    306     268     429
#> ph.ecog=2  50     44    199     156     288
#> ph.ecog=3   1      1    118      NA      NA
```

Note: because there was only 1 bedridden patient, the median survival time is the survival time of that patient, and there is no confidence interval provided.

---

## Comparing Survival Across Groups

The **log-rank test** is a standard test for comparing groups when we have survival data. Here we use it to test the null hypothesis that there is no difference in survival between the groups, versus the alternative that there is a difference in survival.

```r
survdiff(Surv(time,status)~ph.ecog, data=lung)
```

```
#> Call:
#> survdiff(formula = Surv(time, status) ~ ph.ecog, data = lung)
#> 
#> n=227, 1 observation deleted due to missingness.
#> 
#>             N Observed Expected (O-E)^2/E (O-E)^2/V
#> ph.ecog=0  63       37   54.153    5.4331    8.2119
#> ph.ecog=1 113       82   83.528    0.0279    0.0573
#> ph.ecog=2  50       44   26.147   12.1893   14.6491
#> ph.ecog=3   1        1    0.172    3.9733    4.0040
#> 
#>  Chisq= 22  on 3 degrees of freedom, p= 7e-05
```

Here we see `$p<0.0001$` and reject the null hypothesis, concluding that there is evidence in the data of a difference in survival across the groups.

---

## Cox Proportional Hazards Model

Suppose we have multiple covariates of interest. For example, in the lung cancer data, we also have covariates like `wt.loss` (weight loss in the past 6 months) and `age`.  If we want to fit a model to survival data, the **Cox proportional hazards model** is a popular choice.

The Cox proportional hazards model has a couple of important assumptions that are beyond the scope of this course (non-informative censoring, meaning censoring times are unrelated to the unobserved failure time, and the proportional hazards assumption, meaning that the hazards of failure are proportional across groups). You should explore these more if you plan to model survival data.

---

## Cox Model for Lung Cancer Data

```r
library(gtsummary)

coxph(Surv(time, status) ~ 
        as.factor(ph.ecog)+
        wt.loss+age, 
      data = lung) %>%
    tbl_regression(exp = TRUE) 
```

<div id="davptpvuum" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
 font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#davptpvuum .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#davptpvuum .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#davptpvuum .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#davptpvuum .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#davptpvuum .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#davptpvuum .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#davptpvuum .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#davptpvuum .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#davptpvuum .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#davptpvuum .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#davptpvuum .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#davptpvuum .gt_group_heading {
  padding: 8px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#davptpvuum .gt_empty_group_heading {
  padding: 0.5px;
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#davptpvuum .gt_from_md > :first-child {
  margin-top: 0;
}

#davptpvuum .gt_from_md > :last-child {
  margin-bottom: 0;
}

#davptpvuum .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#davptpvuum .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#davptpvuum .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#davptpvuum .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#davptpvuum .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#davptpvuum .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#davptpvuum .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#davptpvuum .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#davptpvuum .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#davptpvuum .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#davptpvuum .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#davptpvuum .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#davptpvuum .gt_left {
  text-align: left;
}

#davptpvuum .gt_center {
  text-align: center;
}

#davptpvuum .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#davptpvuum .gt_font_normal {
  font-weight: normal;
}

#davptpvuum .gt_font_bold {
  font-weight: bold;
}

#davptpvuum .gt_font_italic {
  font-style: italic;
}

#davptpvuum .gt_super {
  font-size: 65%;
}

#davptpvuum .gt_footnote_marks {
 font-style: italic;
 font-weight: normal;
 font-size: 65%;
}
</style>
<table class="gt_table">
 
 <thead class="gt_col_headings">
 <tr>
 <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1">Characteristic</th>
 <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1">HR1</th>
 <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1">95% CI1</th>
 <th class="gt_col_heading gt_columns_bottom_border gt_center" rowspan="1" colspan="1">p-value</th>
 </tr>
 </thead>
 <tbody class="gt_table_body">
 <tr><td class="gt_row gt_left">as.factor(ph.ecog)</td>
<td class="gt_row gt_center"></td>
<td class="gt_row gt_center"></td>
<td class="gt_row gt_center"></td></tr>
 <tr><td class="gt_row gt_left" style="text-align: left; text-indent: 10px;">0</td>
<td class="gt_row gt_center">—</td>
<td class="gt_row gt_center">—</td>
<td class="gt_row gt_center"></td></tr>
 <tr><td class="gt_row gt_left" style="text-align: left; text-indent: 10px;">1</td>
<td class="gt_row gt_center">1.47</td>
<td class="gt_row gt_center">0.98, 2.20</td>
<td class="gt_row gt_center">0.064</td></tr>
 <tr><td class="gt_row gt_left" style="text-align: left; text-indent: 10px;">2</td>
<td class="gt_row gt_center">2.50</td>
<td class="gt_row gt_center">1.52, 4.10</td>
<td class="gt_row gt_center"><0.001</td></tr>
 <tr><td class="gt_row gt_left" style="text-align: left; text-indent: 10px;">3</td>
<td class="gt_row gt_center">9.86</td>
<td class="gt_row gt_center">1.29, 75.5</td>
<td class="gt_row gt_center">0.028</td></tr>
 <tr><td class="gt_row gt_left">wt.loss</td>
<td class="gt_row gt_center">0.99</td>
<td class="gt_row gt_center">0.98, 1.01</td>
<td class="gt_row gt_center">0.3</td></tr>
 <tr><td class="gt_row gt_left">age</td>
<td class="gt_row gt_center">1.01</td>
<td class="gt_row gt_center">0.99, 1.03</td>
<td class="gt_row gt_center">0.2</td></tr>
 </tbody>
 
 <tfoot>
 <tr class="gt_footnotes">
 <td colspan="4">
 
 
 1
 
 
 HR = Hazard Ratio, CI = Confidence Interval
 
 
 </td>
 </tr>
 </tfoot>
</table>
</div>
]
.pull-right[
The estimates labeled `exp(coef)` are interpreted as *hazard ratios*. That is, patients who spend >50% of their time in bed but who are not bedridden (group 2) have 2.5 times the hazard of failure as patients with no symptoms, conditional on age and weight loss.
]

---

## Hazard Ratio (HR)

- The HR represents the ratio of hazards between two groups at any particular point in time.

- The HR compares instantaneous rates of occurrence of the event of interest in those who are still at risk for the event.

- HR < 1 indicates reduced hazard of death; HR > 1 indicates an increased hazard of death

So our HR = 2.5 implies that around 2.5 times as many people who are bedridden are dying as those who are asymptomatic, at any given time, conditional on age and weight loss.

---

## Interpretation Summary (No Interactions in Model)

- Linear regression: interpret estimate `$\hat{\beta}_1$` corresponding to covariate `$x_1$` as *the expected increase in `$y_i$` corresponding to a one-unit increase in `$x_{1}$`, holding all other factors constant*

- Logistic regression: interpret estimate `$\exp(\hat{\beta}_1)$` corresponding to covariate `$x_1$` as *the ratio of odds of `$y_i=1$` comparing those with `$x_{1}=c+1$` to those with `$x_{1}=c$` (or corresponding to a 1-unit increase in the value of `$x_1$`), holding all other factors constant*
- Cox proportional hazards (survival) model: interpret estimate `$\exp(\hat{\beta}_1)$` corresponding to covariate `$x_1$` as *the ratio of hazards of failure comparing those with `$x_{1}=c+1$` to those with `$x_{1}=c$` (or corresponding to a 1-unit increase in the value of `$x_1$`), holding all other factors constant*